ArticleScientific reports2026
Skeletal rearrangement in Biginelli reaction for the synthesis of chromenoquinoline fused spirohydantoins and their in silico cytotoxicity study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although Biginelli reaction is known to generate dihydropyrimidinones having wide arrays of phramacological properties, herein we report an unprecedented skeletal rearrangement in Biginelli reaction to synthesize pharmacologically versatile imidazolidine-2,4-diones, popularly known as hydantoins. Here a mixture of isatin, 4-hydroxycoumarin and 1,3-dimethylurea reacts in the presence of a catalytic amount of p-TsOH to generate spirohydantoins fused with chromenoquinoline moiety. Skeletal rearrangement of the 5-membered keto-lactam ring of isatin to a structurally constrained 5-membered ring in the form of spirohydantoins is the most interesting feature of this protocol. Nonetheless, the reaction introduces a novel molecular architecture bearing medicinally important spirohydantoin and chromenoquinoline scaffolds. In-silico molecular docking simulation of the synthesized compounds against human kinesin Eg5 (PDB ID: 2IEH) along with 17 other tumor-associated targets demonstrated strong binding efficiency, indicating that these compounds merit further biological evaluation to validate their anticancer potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.